Ignite Creation Date:
2024-05-05 @ 10:17 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00004567
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
2000-02-11
Brief Title:
Comparison of Treatments to Maintain Disease Remission in Patients With Wegeners Granulomatosis and Related Vasculitis Syndromes
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
A Randomized Trial Comparing Methotrexate Versus Mycophenolate Mofetil for Remission Maintenance in Wegeners Granulomatosis and Related Vasculitides
Status:
COMPLETED
Status Verified Date:
2004-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will compare the safety and effectiveness of two drugs-methotrexate and mycophenolate mofetil MPM-in preventing disease recurrence in patients with Wegeners granulomatosis and related inflammatory blood vessel disorders The standard treatment for these conditions is combination drug therapy with prednisone plus cyclophosphamide However although most patients improve on this therapy and achieve disease remission many experience a relapse return of the disease some time after therapy is stopped Also these drugs can produce serious side effects during treatment This study will test a new treatment regimen to try to maintain disease remission in these patients with minimal side effects
Patients with Wegeners granulomatosis or other related blood vessel disorders between 10 and 80 years old will be considered for this study All participants will start therapy with daily doses of prednisone and cyclophosphamide Prednisone will be reduced gradually and then stopped after symptoms improve significantly Cyclophosphamide will continue until the disease is in remission Patients in remission will then be randomly assigned to continue treatment with either MPM or methotrexate MPM is taken twice a day by mouth Methotrexate is taken once a week usually by mouth but in some cases by injection into a muscle or under the skin Patients who do well and have no side effects will continue treatment for 2 years Then the drug will gradually be reduced usually at monthly intervals and finally stopped No further treatment will be given unless a relapse occurs At that time the type of treatment will depend on various medical factors including the severity of the recurrence and the patients history of drug side effects
Physical examinations and various tests including blood and urine analyses and X-rays will be done periodically to evaluate the response to treatment and monitor drug side effects The total duration of the study-from the screening evaluation through a 2-year follow up after all medications have been stopped-is about 5 to 6 years
Patients with Wegeners granulomatosis or other related blood vessel disorders between 10 and 80 years old will be considered for this study All participants will start therapy with daily doses of prednisone and cyclophosphamide Prednisone will be reduced gradually and then stopped after symptoms improve significantly Cyclophosphamide will continue until the disease is in remission Patients in remission will then be randomly assigned to continue treatment with either MPM or methotrexate MPM is taken twice a day by mouth Methotrexate is taken once a week usually by mouth but in some cases by injection into a muscle or under the skin Patients who do well and have no side effects will continue treatment for 2 years Then the drug will gradually be reduced usually at monthly intervals and finally stopped No further treatment will be given unless a relapse occurs At that time the type of treatment will depend on various medical factors including the severity of the recurrence and the patients history of drug side effects
Physical examinations and various tests including blood and urine analyses and X-rays will be done periodically to evaluate the response to treatment and monitor drug side effects The total duration of the study-from the screening evaluation through a 2-year follow up after all medications have been stopped-is about 5 to 6 years
Detailed Description:
The purpose of this study is to assess the comparative efficacy of using methotrexate versus mycophenolate mofetil for maintaining remission that has been induced by cyclophosphamide and glucocorticoids in patients with Wegeners granulomatosis and related vasculitides In this study all patients will initially receive daily cyclophosphamide and glucocorticoids and then at disease remission cyclophosphamide will be discontinued and patients will be randomized to receive either methotrexate or mycophenolate mofetil for remission maintenance They will continue to receive the agent to which they are randomized for 2 years after which time it will be tapered and discontinued Patients will be prospectively monitored for evidence of disease relapse and drug toxicity Specific parameters that will be obtained include the time to disease remission the rate and time of disease relapse and the incidence of drug-related adverse events
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 00-I-0075 | None | None | None |